Skip to main content

VitalHub Announces Acquisition of Buddy Healthcare

TORONTO, July 13, 2026 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (“VitalHub” or the “Company”) announced today that it has acquired Buddy Healthcare Ltd Oy (“Buddy Healthcare”), a care coordination platform based in Finland. Transaction Details VitalHub has acquired Buddy Healthcare for total up-front consideration of €8.6 million, plus potential performance-based consideration. The purchase price paid at closing was composed of a cash payment of €8.3 million, subject to working capital adjustments, and the issuance of 75,000 common shares of VitalHub. The maximum amount payable under the all-cash earnouts is €4.5 million based on the achievement of performance-based targets at the end of the first two calendar years post-acquisition. Overview of Buddy Healthcare Established in 2016, Buddy Healthcare is a leading...

Continue reading

First Hawaiian, Inc. to Acquire TriCo Bancshares and Provide Preliminary 2026 Second Quarter Results

The transaction creates the leading Pacific banking franchise, accelerating mainland growth while combining strong deposit platforms and delivering compelling shareholder value HONOLULU and CHICO, Calif., July 13, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) (“First Hawaiian”), parent company of First Hawaiian Bank, and TriCo Bancshares (NASDAQ: TCBK) (“TriCo”), parent company of Tri Counties Bank, today announced they have entered into a definitive agreement pursuant to which First Hawaiian will acquire TriCo in an all-stock transaction. This partnership combines two culturally aligned, relationship-driven banking franchises with attractive deposit bases, disciplined credit cultures and deep local market positions. On a combined basis, the company will have approximately $34 billion of assets...

Continue reading

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Joshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, LongeveronPoster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI” presented at July 13th In Person Poster Presentation Session Results support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimer’s disease Longeveron has received U.S. FDA RMAT designation for its Alzheimer’s disease program and has aligned on a Phase 3 study designMIAMI,...

Continue reading

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen’s novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone...

Continue reading

Fury Reports Intercept of 7.0 g/t Gold over 21.0 Metres at Eau Claire and Mobilizes Third Drill Rig

No other intercept of comparable true thickness has returned as high a grade at Eau Claire to date TORONTO, July 13, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce the second batch of assay results (8 holes, 5,064 metres (m)) from its ongoing Phase 2 (15,000–25,000-metre) drill program at the Eau Claire gold project (“Eau Claire” or the “Project”), and that it has mobilized a third diamond drill rig to the site. The Project is located in the Eeyou Istchee Territory in the James Bay Region of Northern Quebec. The most significant result from this batch of drilling is conversion drill hole 26EC-115, which tested an inferred portion of the mineral resource approximately 52 m down strike of drill hole 26EC-102...

Continue reading

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists. Full results to be presented at an upcoming medical meetingPRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic...

Continue reading

Serstech receives 12.6 MSEK order from South Korea

Serstech has today received an order from its South Korean partner Young Jin Solutec Co. Ltd with a total value of 12.6 MSEK. The order consists of instruments and software and will be delivered and invoiced during the third quarter of 2026.For further information, please contact: Stefan Sandor, CEO, Serstech AB Phone: +46 739 606 067 Email: ss@serstech.com or Arve Nilsson, Chairman of the Board, Serstech AB Phone: +45 40 35 82 65 Email: arve.nilsson@serstech.com or visit: www.serstech.com This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 12:45 CET on July 13, 2026. Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG). About Serstech Serstech delivers...

Continue reading

Bullish appoints Thomas Cowan as Head of Tokenization

GEORGE TOWN, Cayman Islands, July 13, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, today announced the appointment of Thomas Cowan as Head of Tokenization. Cowan will lead the company’s tokenization strategy, building on the foundation Bullish has assembled through its regulated exchange infrastructure, CoinDesk’s market data and indices services, and upon completion of its pending acquisition, Equiniti’s global transfer agent and registry capabilities, to establish the company as the market infrastructure for tokenized securities. Cowan joins Bullish from Galaxy, where he led the firm’s institutional tokenization business, pioneering the initiative behind Galaxy becoming the first Nasdaq-listed...

Continue reading

Brookfield Corporation to Host Second Quarter 2026 Results Conference Call

BROOKFIELD, NEWS, July 13, 2026 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) will host its second quarter 2026 conference call and webcast on Thursday, August 13, 2026, at 10:00am (ET). Results will be released that morning at approximately 7:00am (ET) and available on our website at https://bn.brookfield.com/events-news/press-releases Participants can join by conference call or webcast: Conference CallPlease pre-register by conference call:https://register-conf.media-server.com/register/BI33fe6ec1392e4d5b96be7ae5bf3808cfUpon registering, you will be emailed a dial-in number, and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register by webcast: https://edge.media-server.com/mmc/p/54f6ymvp Replay of the event is available on the above webcast link for 90...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – IP GROUP PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.